Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  BG ControlType 2 DiabetesNephrologyOphthalmologyNeuropathyInsulinIssue 730

Long-term Diabetes Complications and Intensive Treatment Effects

Compared with routine care, early intensive multifactorial therapy shows little effect.... 

Advertisement

In an effort to determine the benefit of multifactorial treatment on microvascular complications among people with type 2 diabetes, Annelli Sandbaek, MD, PhD, and colleagues conducted a multicenter cluster randomized controlled trial at four centers in Denmark, the UK, and The Netherlands. Out of 3,057 people with diabetes detected by a screening process, only 2,861 were eligible for follow-ups. They were assigned to either the intensive treatment or routine care group.

The results from the four centers were collected using a fixed-effects meta-analysis. Of the patients who received intensive treatment, 22.7% showed any type of albuminuria, and patients who underwent routine care had 24.4%. Retinopathy was observed in 10.2% of the patients who underwent intensive treatment, whereas 12.1% was seen in routine care patients. When it came to neuropathy, 4.9% was seen in intensive treatment patients, and 5.9% in routine care patients. However, in both groups the estimated glomerular filtration rate increased between baseline and follow-up; 4.31 mL/min was seen in the intensive treatment and 6.44 mL/min in the routine care groups.

According to the results of this study, researchers stated, "Compared with routine care, an intervention to promote target-driven, intensive management of patients with type 2 diabetes detected by screening was not associated with significant reductions in the frequency of microvascular events at five years."

Practice Pearls:
  • Albuminuria was 22.7% in the intensive group compared to 24% in the routine care group.
  • Retinopathy was present in 10.2% of the patients who underwent intensive treatment, whereas 12.1% was seen in routine care patients
  • Neuropathy, 4.9%, was seen in intensive treatment patients, and 5.9% in routine care

Sandbaek A et al. Diabetes Care. 2014; doi: 10.2337/dc13-1544 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 May, 2014 and appeared in  BG ControlType 2 DiabetesNephrologyOphthalmologyNeuropathyInsulinIssue 730

Past five issues: SGLT-2 Inhibitors Special Edition July 2015 | Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
Posted July 17, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
Ancestral Diets Can Determine Vulnerability to Type 2 Diabetes
Posted July 17, 2015
Impact of Exercise in Type 2 Diabetes Patients
Posted July 23, 2015
Two Gene Mutations Identified in Increased Risk of Obesity and Diabetes
Posted July 23, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you have any patients on a dual therapy of a DPP-4 and a SGLT-2 who have reached their goal A1c?

CME/CE of the Week
Marie Williams, DPM

Category: Wound Care
Credits: .75